Article
Patient-reported outcomes after switching from brand-name to generic drospirenone/ethinylestradiol combined oral contraceptives: a questionnaire-based observational study
2026-02-09
Abstract excerpt
<title>Abstract</title> <p>Background In Japan, the term “low-dose estrogen–progestin (LEP)” refers to combined oral contraceptive (COC) formulations that are pharmacologically equivalent to COCs but are primarily approved for therapeutic indications rather than contraception. Although bioequivalence between brand-name and generic formulations is required, patients sometimes report subjective differences after s...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 632f002f-a588-5410-a5e8-8cd164e1a595
- DOI
- 10.21203/rs.3.rs-8735703/v1
